OBJECTIVE: This study aimed to evaluate the role of angiotensin type 1 receptor gene (AGTR1) polymorphism (A1166C) in left ventricular hypertrophy (LVH) mediated by the angiotensin-converting enzyme (ACE) in endurance athletes. METHODS: A group of 74 white, healthy male endurance athletes, aged between 25 and 40 yr, were enrolled in this study. All of them participated primarily in isotonic sports, training for at least >10 h x wk(-1), for at least 5 yr. The ACE genotype (insertion [I] or deletion [D] alleles) was ascertained by polymerase chain reaction (DD in 35, ID in 36, and II in 3). Group II was excluded from the analysis because of its small size. No difference was found between the two groups as regards age, blood pressure, HR, and echocardiographic data. RESULTS: The left ventricular mass index (LVMI) was significantly higher in group DD rather than in group ID (P = 0.029). The group DD showed a slightly higher prevalence of subjects with LVH (LVMI > 131 g x m(-2); 62.9%) than group ID (44.4%, P = 0.120). No association was found between ACE-DD and LVH (odds ratio (OR) = 2.12, 95% confidence interval = 0.82-5.46). Concerning the role of AGTR1 polymorphism, the highest LVMI was found in 15 athletes with ACE-DD and AGTR1-AC/CC genotypes (150 +/- 23 g x m(-2)); the lowest value of LVMI was found in the case of ACE-ID and AGTR1-AA (127 g x m(-2) +/- 18 g x m(-2)), whereas LVMI in subjects with ACE-DD + AGTR1-AA was similar to that in the ACE-ID + AGTR1-AC/CC group (134 +/- 18 g x m(-2) vs 133 +/- 20 g x m(-2), P = 0.880). The presence of ACE-DD + AGTR1 + AC/CC was strongly associated with LVH (OR = 4.6, P = 0.029). Moreover, subjects with LVH showed longer left ventricular isovolumetric relaxation time and higher end-systolic wall stress. The latter was strongly correlated to LVMI (r = 0.588), especially in the presence of ACE-DD + AGTR1 + AC/CC (r = 0.728). CONCLUSIONS: LVMI may be greater in the presence of ACE- DD and AGTR1-AC/CC polymorphisms.
OBJECTIVE: This study aimed to evaluate the role of angiotensin type 1 receptor gene (AGTR1) polymorphism (A1166C) in left ventricular hypertrophy (LVH) mediated by the angiotensin-converting enzyme (ACE) in endurance athletes. METHODS: A group of 74 white, healthy male endurance athletes, aged between 25 and 40 yr, were enrolled in this study. All of them participated primarily in isotonic sports, training for at least >10 h x wk(-1), for at least 5 yr. The ACE genotype (insertion [I] or deletion [D] alleles) was ascertained by polymerase chain reaction (DD in 35, ID in 36, and II in 3). Group II was excluded from the analysis because of its small size. No difference was found between the two groups as regards age, blood pressure, HR, and echocardiographic data. RESULTS: The left ventricular mass index (LVMI) was significantly higher in group DD rather than in group ID (P = 0.029). The group DD showed a slightly higher prevalence of subjects with LVH (LVMI > 131 g x m(-2); 62.9%) than group ID (44.4%, P = 0.120). No association was found between ACE-DD and LVH (odds ratio (OR) = 2.12, 95% confidence interval = 0.82-5.46). Concerning the role of AGTR1 polymorphism, the highest LVMI was found in 15 athletes with ACE-DD and AGTR1-AC/CC genotypes (150 +/- 23 g x m(-2)); the lowest value of LVMI was found in the case of ACE-ID and AGTR1-AA (127 g x m(-2) +/- 18 g x m(-2)), whereas LVMI in subjects with ACE-DD + AGTR1-AA was similar to that in the ACE-ID + AGTR1-AC/CC group (134 +/- 18 g x m(-2) vs 133 +/- 20 g x m(-2), P = 0.880). The presence of ACE-DD + AGTR1 + AC/CC was strongly associated with LVH (OR = 4.6, P = 0.029). Moreover, subjects with LVH showed longer left ventricular isovolumetric relaxation time and higher end-systolic wall stress. The latter was strongly correlated to LVMI (r = 0.588), especially in the presence of ACE-DD + AGTR1 + AC/CC (r = 0.728). CONCLUSIONS: LVMI may be greater in the presence of ACE- DD and AGTR1-AC/CC polymorphisms.
Authors: Zudin Puthucheary; James R A Skipworth; Jai Rawal; Mike Loosemore; Ken Van Someren; Hugh E Montgomery Journal: Sports Med Date: 2011-06-01 Impact factor: 11.136
Authors: Manal F Elshamaa; Samar M Sabry; Hafez M Bazaraa; Hala M Koura; Eman A Elghoroury; Nagwa A Kantoush; Eman H Thabet; Dalia A Abd-El Haleem Journal: J Inflamm (Lond) Date: 2011-08-23 Impact factor: 4.981
Authors: Armin Arbab-Zadeh; Merja Perhonen; Erin Howden; Ronald M Peshock; Rong Zhang; Beverly Adams-Huet; Mark J Haykowsky; Benjamin D Levine Journal: Circulation Date: 2014-10-03 Impact factor: 29.690
Authors: Pascal Izzicupo; Maria A D'Amico; Andrea Di Blasio; Giorgio Napolitano; Fabio Y Nakamura; Angela Di Baldassarre; Barbara Ghinassi Journal: Front Endocrinol (Lausanne) Date: 2017-12-21 Impact factor: 5.555
Authors: Pascal Izzicupo; Andrea Di Blasio; Andrea Di Credico; Giulia Gaggi; Anastasios Vamvakis; Giorgio Napolitano; Fabrizio Ricci; Sabina Gallina; Barbara Ghinassi; Angela Di Baldassarre Journal: Int J Environ Res Public Health Date: 2020-04-28 Impact factor: 3.390
Authors: Giulia Gaggi; Andrea Di Credico; Pascal Izzicupo; Ivana Antonucci; Clara Crescioli; Viviana Di Giacomo; Annalisa Di Ruscio; Giovanni Amabile; Francesco Alviano; Angela Di Baldassarre; Barbara Ghinassi Journal: Cells Date: 2020-05-24 Impact factor: 6.600
Authors: Angela Di Baldassarre; Maria A D'Amico; Pascal Izzicupo; Giulia Gaggi; Simone Guarnieri; Maria A Mariggiò; Ivana Antonucci; Barbara Corneo; Dario Sirabella; Liborio Stuppia; Barbara Ghinassi Journal: Sci Rep Date: 2018-08-13 Impact factor: 4.379